Lv2
118 积分 2024-03-08 加入
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
4天前
已完结
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
4天前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
11天前
已完结
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
20天前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
26天前
已完结
684 - Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY
1个月前
已完结
684 - Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY
1个月前
已关闭
190 Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
2个月前
已完结
495 - Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
2个月前
已关闭
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
3个月前
已完结
皖公网安备34019202002308
